1. PROTAC Metabolic Enzyme/Protease
  2. PROTACs HMG-CoA Reductase (HMGCR)
  3. PROTAC HMGCR Degrader-1

PROTAC HMGCR Degrader-1 is an orally active HMGCR PROTAC degrader with IC50 of 1.32 μM. PROTAC HMGCR Degrader-1 is a lactone prodrug of PROTAC HMGCR Degrader-2 (HY-181134). PROTAC HMGCR Degrader-1 achieves high plasma exposure of the active ingredient leading to robust HMGCR degradation and demonstrating promising cholesterol-lowering efficacy in vivo. PROTAC HMGCR Degrader-1 can be used for hyperlipidemia research.

For research use only. We do not sell to patients.

PROTAC HMGCR Degrader-1

PROTAC HMGCR Degrader-1 Chemical Structure

CAS No. : 2715104-45-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All PROTACs Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PROTAC HMGCR Degrader-1 is an orally active HMGCR PROTAC degrader with IC50 of 1.32 μM. PROTAC HMGCR Degrader-1 is a lactone prodrug of PROTAC HMGCR Degrader-2 (HY-181134). PROTAC HMGCR Degrader-1 achieves high plasma exposure of the active ingredient leading to robust HMGCR degradation and demonstrating promising cholesterol-lowering efficacy in vivo. PROTAC HMGCR Degrader-1 can be used for hyperlipidemia research[1].

In Vitro

PROTAC HMGCR Degrader-1 (compound 21 b) is a lactone prodrug of PROTAC HMGCR Degrader-2 (HY-181134) (compound 21 c). PROTAC HMGCR Degrader-2 is a HMGCR PROTAC degrader degrading HMGCR in Insig-silenced HepG2 cells with DC50 of 120 nM through a VHL-dependent manner [1].
PROTAC HMGCR Degrader-1 (0.01-3 μM, 16 h) preferentially acts as HMGCR inhibitors over degraders at high doses in HepG2 cells, achieves a maximum degradation (Dmax) of 56% at a high dose of 1 μM[1].
PROTAC HMGCR Degrader-1 (1 μM, 16 h) prevents the compensatory upregulation of HMGCR in human hepatic HepG2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.01. 0.03, 0.1, 0.3, 1 and 3 μM
Incubation Time: 16 h
Result: Attenuated the upregulation of HMGCR at low concentration.
Increase in HMGCR expression at high concentration.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 1 μM
Incubation Time: 16 h
Result: Effectively attenuated the compensatory upregulation of HMGCR.
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUC0-24 AUC0-∞
Mice[1] 60 mg/kg p.o. 5.1 h 8.0 h 0.47 μM 5.0 μM 5.4 μM
In Vivo

PROTAC HMGCR Degrader-1 (compound 21 b) (20 or 60 mg/kg. p.o., once a day for 5 weeks) suppress de novo cholesterol synthesis via HMGCR degradation at low dose and exert better effects for promoting excretion of redundant lipids absorbed daily from an MFD27 when cotreat with synergetic statin with well safety profile in medium fat diet (MFD)-induced mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MFD (medium-fat containing 12% fat, 0.5% so dium cholate and 1.25% cholesterol) (8 weeks) induced-male C57BL/6 mice (20e24 g)[1]
Dosage: 20 or 60 mg/kg
Administration: p.o., once a day for 5 weeks
Result: Was well tolerated, with no significant change in body weight and food intake.
Demonstrated similar effects to lovastatin.
Decreased total cholesterol (TC), LDL-C and triglyceride (TG) in serum of mice fed on MFD.
Enhanced the reduction in serum lipid levels when combination with lovastatin.
Reduced serum TC and cholesteryl esters to lower levels at a higher dose of 60 mg/kg.
Reduced hepatic TC and TG in a dose-dependent manner.
Ameliorated MFD-induced steatosis and lipid deposition in liver sections.
Induced robust HMGCR degradation at 16 h after final gavage even at a low dose of 20 mg/kg.
Was more effective in lowering total lipids (TC, cholesteryl ester and TG) when cotreated with lovastatin.
Molecular Weight

960.27

Formula

C53H77N5O9S

CAS No.
SMILES

O=C(O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@]12[H])NCCCCCCCCCCC(N[C@@H](C(C)(C)C)C(N4[C@H](C(NCC5=CC=C(C6=C(C)N=CS6)C=C5)=O)C[C@@H](O)C4)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PROTAC HMGCR Degrader-1
Cat. No.:
HY-171823
Quantity:
MCE Japan Authorized Agent: